Kartos Therapeutics
Kartos Therapeutics is a clinical stage biopharmaceutical company dedicated to developing novel, targeted therapeutics that improve the lives of patients with cancer. They focus on the MDM2-p53 interaction as a therapeutic target and are developing navtemadlin (KRT-232), an MDM2 inhibitor, for cancer treatment.
Industries
Nr. of Employees
small (1-50)
Kartos Therapeutics
275 Shoreline Drive, Suite 300, Redwood City, CA 94065
Patents
Products
Investigational oral MDM2 inhibitor
An investigational, orally administered small-molecule inhibitor that targets the MDM2–p53 interaction; progressed into human clinical trials for myelofibrosis and evaluated across other oncology indications.
Investigational oral MDM2 inhibitor
An investigational, orally administered small-molecule inhibitor that targets the MDM2–p53 interaction; progressed into human clinical trials for myelofibrosis and evaluated across other oncology indications.
Services
Evaluation of physician-submitted requests for investigational agent access outside clinical trials with a formal review process and commitment to respond within a stated timeframe.
Evaluation of physician-submitted requests for investigational agent access outside clinical trials with a formal review process and commitment to respond within a stated timeframe.
Expertise Areas
- Clinical trial management
- Oncology drug development
- Targeted small-molecule therapeutics
- MDM2–p53 pathway biology
Key Technologies
- MDM2–p53 protein–protein interaction targeting
- Oral small-molecule inhibitor development
- Phase 1b/2 and Phase 3 clinical trial methodologies
- Clinical trial registration and public disclosure
News & Updates
A Phase 3, randomized, double-blind, add-on study evaluating the safety and efficacy of Navtemadlin plus Ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis who have a suboptimal response to Ruxolitinib.
An open-label, multicenter, Phase 1b/2 study of the safety and efficacy of Navtemadlin (KRT-232) combined with Ruxolitinib in patients with primary myelofibrosis, post-polycythemia vera MF, or post-essential thrombocythemia MF who have a suboptimal response to Ruxolitinib.
Navtemadlin (KRT-232) versus best available therapy for the treatment of subjects with myelofibrosis who are relapsed or refractory to JAK inhibitor treatment.
An open-label, multicenter, Phase 2 study assessing the safety and efficacy of Navtemadlin (KRT-232) in JAK inhibitor treatment-naïve myelofibrosis patients.
A Phase 3, randomized, double-blind, add-on study evaluating the safety and efficacy of Navtemadlin plus Ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis who have a suboptimal response to Ruxolitinib.
An open-label, multicenter, Phase 1b/2 study of the safety and efficacy of Navtemadlin (KRT-232) combined with Ruxolitinib in patients with primary myelofibrosis, post-polycythemia vera MF, or post-essential thrombocythemia MF who have a suboptimal response to Ruxolitinib.
Navtemadlin (KRT-232) versus best available therapy for the treatment of subjects with myelofibrosis who are relapsed or refractory to JAK inhibitor treatment.
An open-label, multicenter, Phase 2 study assessing the safety and efficacy of Navtemadlin (KRT-232) in JAK inhibitor treatment-naïve myelofibrosis patients.